Neuroregenerative Activity of the Dipeptide Mimetic of Brain-derived Neurotrophic Factor GSB-106 Under Experimental Ischemic Stroke
Background: A dimeric dipeptide mimetic of the BDNF loop 4, bis(N-monosuccinyl- L-seryl-L-lysine) hexamethylenediamide (GSB-106) activates TrkB, PI3K/AKT, MAPK/ ERK, and PLC-γ1, and was created at the V.V. Zakusov Research Institute of Pharmacology. GSB-106 showed neuroprotective
activity in vitro and in vivo at systemic administration.
Objective: In this work, we studied the GSB-106 effect on the cerebral infarct volume, as well as on neurogenesis and synaptogenesis under the experimental ischemic stroke induced by intravascular occlusion of the middle cerebral artery in rats.
Methods: GSB-106 was administered i.p. in a dose of 0.1 mg/kg, 24 h after the surgery and then once a day, with the end of administration on day 6 after surgery. On day 7, brain samples were collected for morphometric and biochemical (Western-blot) analysis.
Results: It was established that GSB-106 reduced the brain damage volume by 24%, restored impaired neurogenesis and/or gliogenesis (by Ki-67) in the hippocampus and the striatum, and completely restored the reduced immunoreactivity to synaptic markers synaptophysin and PSD-95 in the striatum.
Conclusion: Thus, the dimer dipeptide BDNF mimetic GSB-106 exhibits neuroregenerative properties at a clinically relevant time window (24 h) in a model of ischemic stroke presumably due to the stimulation of neurogenesis (and/or gliogenesis) and synaptogenesis.
Objective: In this work, we studied the GSB-106 effect on the cerebral infarct volume, as well as on neurogenesis and synaptogenesis under the experimental ischemic stroke induced by intravascular occlusion of the middle cerebral artery in rats.
Methods: GSB-106 was administered i.p. in a dose of 0.1 mg/kg, 24 h after the surgery and then once a day, with the end of administration on day 6 after surgery. On day 7, brain samples were collected for morphometric and biochemical (Western-blot) analysis.
Results: It was established that GSB-106 reduced the brain damage volume by 24%, restored impaired neurogenesis and/or gliogenesis (by Ki-67) in the hippocampus and the striatum, and completely restored the reduced immunoreactivity to synaptic markers synaptophysin and PSD-95 in the striatum.
Conclusion: Thus, the dimer dipeptide BDNF mimetic GSB-106 exhibits neuroregenerative properties at a clinically relevant time window (24 h) in a model of ischemic stroke presumably due to the stimulation of neurogenesis (and/or gliogenesis) and synaptogenesis.
Keywords: Brain-derived neurotrophic factor (BDNF); GSB-106; dipeptide mimetic; ischemic stroke; neurogenesis; synaptogenesis
Document Type: Research Article
Publication date: 01 December 2021
This article was made available online on 20 September 2021 as a Fast Track article with title: "Neuroregenerative Activity of the Dipeptide Mimetic of Brain-derived Neurotrophic Factor GSB-106 under Experimental Ischemic Stroke".
- CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content